MBOT earnings analysis
What we found in MBOT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include current-period income statement, balance-sheet, cash-flow, segment, or EPS figures, so no quarter-over-quarter or year-over-year operating trend can be quantified. Management reported effective disclosure controls as of June 30, 2026 and no changes to internal control over financial reporting during the last fiscal quarter. The principal disclosed exposures are uninsured cash balances, foreign-currency fluctuations, and interest-rate sensitivity; no numeric financial guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remained effective
- Management determined that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was reported timely.
- No equity repurchases or unregistered sales
- The company reported no share repurchase activity and no unregistered equity sales during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Uninsured cash concentration
- As of June 30, 2026, Microbot held significant amounts of cash and cash equivalents at one or more financial institutions in excess of federally insured limits, creating potential concentration and uninsured-deposit exposure.
- Foreign-currency exposure
- The company stated that a significant portion of its business and operating expenses are denominated in currencies other than the U.S. dollar; exchange-rate fluctuations could adversely affect future revenues or expenses.
- Interest-rate and investment risk
- Microbot’s cash and cash equivalents as of June 30, 2026 consisted of checking and money market funds, with interest income sensitive to U.S. interest-rate changes; the company also noted that future investments could experience adverse changes in market value.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; numeric guidance fields are therefore null.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Microbot Medical's Q4 2026 report showed no revenue, significantly below the estimated $180,000, while the diluted EPS improved to -$0.04, better than the previous quarter's -$0.07. This loss trajectory may reflect…
- 10-K · March 26, 2026
- Microbot Medical achieved regulatory and commercialization milestones in 2025 — including FDA 510(k) clearance (Sept 8, 2025) and a limited market release (Nov 2025) with Emory University Hospital adoption — but has not…
- 10-Q · August 12, 2025
- Microbot (MBOT) reported a Q2 net loss of $3.5M (EPS $(0.10)) and continues to have no revenues. Liquidity materially improved — cash and marketable securities totaled approximately $32,674 as of June 30, 2025 — funded…
- 10-Q · May 14, 2025
- Microbot Medical reported no revenues (pre‑commercial) for the quarter and a net loss of $2,601,000 (EPS $(0.08)) for the three months ended March 31, 2025, compared with net loss $2,371,000 (EPS $(0.17)) in Q1 2024.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MBOT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever